<DOC>
	<DOCNO>NCT01566279</DOCNO>
	<brief_summary>The investigator hypothesize certain mutation individual cancer genome predict response Everolimus therapy . To identify possible genetic mutation affect tumor response Everolimus investigator obtain sequence analysis tumor patient treat Everolimus study . Moreover , investigator perform systematic review currently available data identify mutation could predictive increased mTOR activity cancer cell . These mutation describe lead mTOR activation predictive value response Everolimus therapy remain unclear . The investigator use data generate investigator prospective treatment study data literature select patient entry second part trial . In part investigator want test hypothesis select patient base specific genetic mutation increase likelihood response .</brief_summary>
	<brief_title>A Study Identify Biomarker Predictive Response Everolimus Solid Tumors ( CPCT-03 )</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Subjects must provide write informed consent prior performance studyspecific procedures assessment , must willing comply treatment followup Inclusion CPCT02 study Age ≥ 18 year Diagnosis malignant tumor show progressive disease accord investigator opinion WHO performance status ( 02 ) Measurable disease allow volumetric measurement No availability standard care systemic treatment option patient refuse receive standard care chemotherapy treatment A female eligible enter participate study : Nonchildbearing potential Adequate organ system function define protocol Fasting serum cholesterol ≤ 300 mg/dl 7.75 mmol/L fast triglyceride ≤ 2.5 × ULN . Previous treatment mTOR inhibitors/pi3k inhibitors/AKT inhibitor Uncontrolled hypertension define RR &gt; 160/95 mmHg Serious nonhealing wound , ulcer bone fracture Within 7 day surgery ( include minor procedure ) Known and/or symptomatic intracerebral metastasis Pregnancy breast feeding , reproductive potential use effective birth control method Severe medical condition ( ) prohibit participation study Use investigational agent last 28 day prior study treatment start Unable unwilling discontinue use interact medication modify dose interact drug least 14 day five halflives drug ( whichever longer ) prior first dose study drug duration study Less four week regular treatment/ palliative radiotherapy Prolongation Fridericia correct QT interval ( QTcF ) &gt; 480 millisecond Any severe / uncontrolled medical condition : 1 . Unstable angina pectoris , symptomatic congestive heart failure myocardial infarction ≤6 month prior enrollment , serious uncontrolled cardiac arrhythmia 2 . Uncontrolled diabetes define fast serum glucose &gt; 1.5 × ULN 3 . Acute chronic , active infectious disorder nonmalignant medical illness uncontrolled whose control may jeopardize complication study therapy 4 . Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption study drug 5 . Significant symptomatic deterioration lung function . Active , bleed diathesis , oral antivitamin K medication ( except low dose warfarin acetylsalicylic acid equivalent , long INR &lt; 2.0 ) Patients known history HIV seropositivity Patients treat drug recognize strong inhibitor inducer isoenzyme CYP3A within last 5 day prior enrollment Patients receive concomitant immunosuppressive agent chronic corticosteroid use , time study entry except case outline : 1 . Topical application ( e.g . rash ) 2 . Inhaled spray ( e.g . obstructive airway disease ) , 3 . Eye drop 4 . Local injection ( e.g . intraarticular ) allow . 5 . Patients stable low dose corticosteroid least two week enrollment allow case treatment brain metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>comer</keyword>
	<keyword>everolimus</keyword>
	<keyword>biomarker</keyword>
	<keyword>next generation sequence</keyword>
</DOC>